Opus Genetics, Inc. Operating Income Loss

• Opus Genetics, Inc. showed an increase of +37.8% in Operating Income Loss from 2024 to 2025.
• This data is from Opus Genetics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
• XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 17 years of available data (2009 to 2025), Opus Genetics, Inc.'s Operating Income Loss has declined by 497.0%.
• Historical annual values: Fiscal year 2025: -$38.60 million | Fiscal year 2024: -$62.07 million | Fiscal year 2023: -$10.56 million | Fiscal year 2022: $18.23 million | Fiscal year 2021: -$22.71 million | Fiscal year 2020: -$19.97 million | Fiscal year 2019: -$4.19 million | Fiscal year 2018: -$20.54 million | Fiscal year 2017: -$17.35 million | Fiscal year 2016: -$16.41 million | Fiscal year 2015: -$18.26 million | Fiscal year 2014: -$13.27 million | Fiscal year 2013: -$7.98 million | Fiscal year 2012: -$6.58 million | Fiscal year 2011: -$16.13 million | Fiscal year 2010: -$10.31 million | Fiscal year 2009: -$6.47 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026